CDC Flu Update: Activity Continuing to Decrease

Influenza activity in the United States continued to decrease, but remained above the national baseline according to the latest FluView report from the CDC. ILI dropped from 3.2% reported last week to 2.7%. Current data indicate that the 2017-2018 flu season peaked at 7.5% in early February (during week 5). However, 17 states continue to report widespread flu activity and 6 states continue to experience high influenza-like illness (ILI) levels. Hospitalization rates are higher than the end-of-season hospitalization rates for 2014-2015, a high severity, H3N2-predominant season. CDC also is reporting an additional 5 flu-related pediatric deaths during week 11, bringing the total number of flu-related pediatric deaths this season to 133. Flu activity is likely to remain elevated for a number of weeks.

CDC routinely recommends influenza vaccination for all persons 6 months of age and older as long as flu viruses are circulating. While H3N2 viruses remain predominant overall this season, during week 11, influenza B viruses were more frequently reported than influenza A viruses. Early vaccine effectiveness (VE) estimates through February 3, 2018 show that flu vaccine reduced the risk of having to go to the doctor due to flu by 36% overall. VE against H3N2 viruses was 25%. VE against H1N1 67% and VE against B viruses was 42%. CDC recommends prompt treatment with influenza antiviral medications for people who are severely ill and people who are at high risk of serious flu complications who develop flu symptoms. Below is a summary of the key flu indicators for the week ending March 17, 2018 (week 11):

Influenza-like Illness Surveillance: For the week ending March 17, the proportion of people seeing their health care provider for influenza-like illness (ILI) was 2.7%, which is a decrease from last week (3.2%), but still above the national baseline of 2.2%. Nine of 10 regions (Regions 1, 2, 3, 4, 5, 7, 8, 9, and 10) reported a proportion of outpatient visits for ILI at or above their region-specific baseline levels. ILI has been at or above the national baseline for 17 weeks so far this season. Over the past five seasons, ILI has remained at or above baseline for 16 weeks on average with 20 weeks being the longest.
Additional ILINet data, including national, regional, and select state-level data for the current and previous seasons, can be found at

Influenza-like Illness State Activity Indicator Map: Six states experienced high ILI activity (Arizona, Nebraska, South Carolina, South Dakota, Virginia, and Wyoming). Nine states experienced moderate ILI activity (California, Georgia, Kansas, Massachusetts, New Jersey, New Mexico, North Carolina, Pennsylvania, and Rhode Island). New York City, Puerto Rico, the District of Columbia and 17 states experienced low ILI activity (Alabama, Alaska, Arkansas, Colorado, Hawaii, Illinois, Indiana, Iowa, Kentucky, Louisiana, Michigan, Minnesota, Mississippi, Nevada, Oregon, Vermont, and Washington). 18 states experienced minimal ILI activity (Connecticut, Delaware, Florida, Idaho, Maine, Maryland, Missouri, Montana, New Hampshire, New York, North Dakota, Ohio, Oklahoma, Tennessee, Texas, Utah, West Virginia, and Wisconsin).
Additional data, including data for previous seasons, can be found at

Geographic Spread of Influenza Viruses: Widespread influenza activity was reported by 17 states (Alaska, California, Connecticut, Delaware, Indiana, Maine, Maryland, Massachusetts, Nebraska, New Hampshire, New Jersey, New York, Ohio, Oklahoma, Rhode Island, Virginia, and Wisconsin). Regional influenza activity was reported by Guam, Puerto Rico and 26 states (Alabama, Arizona, Arkansas, Colorado, Florida, Georgia, Idaho, Illinois, Iowa, Kansas, Kentucky, Michigan, Minnesota, Mississippi, Missouri, Montana, New Mexico, North Carolina, North Dakota, Pennsylvania, South Carolina, South Dakota, Texas, Utah, Washington, and Wyoming). Local influenza activity was reported by the District of Columbia and five states (Louisiana, Nevada, Oregon, Tennessee, and West Virginia). Sporadic influenza activity was reported by the U.S. Virgin Islands and two states (Hawaii and Vermont).Geographic spread data show how many areas within a state or territory are seeing flu activity.
Additional data are available at:

Flu-Associated Hospitalizations: Since October 1, 2017, 26,694 laboratory-confirmed influenza-associated hospitalizations have been reported through the Influenza Hospitalization Network (FluSurv-NET), a population-based surveillance network for laboratory-confirmed influenza-associated hospitalizations. This translates to a cumulative overall rate of 93.5 hospitalizations per 100,000 people in the United States.
The highest hospitalization rate is among people 65 years and older (401.8 per 100,000), followed by adults aged 50-64 years (101.5 per 100,000), and younger children aged 0-4 years (66.4 per 100,000). During most seasons, adults 65 years and older have the highest hospitalization rates, followed by children 0-4 years.
The rates reported during week 11 are higher than the end-of-season hospitalization rates for all ages (cumulative) and all age-group specific rates for the 2014-2015 flu season.
Hospitalization data are collected from 13 states and represent approximately 9% of the total U.S. population. The number of hospitalizations reported does not reflect the actual total number of influenza-associated hospitalizations in the United States. Additional data, including hospitalization rates during other influenza seasons, can be found at and

Mortality Surveillance:
The proportion of deaths attributed to pneumonia and influenza (P&I) decreased but remained elevated at 7.8% for the week ending March 3, 2018 (week 9). The epidemic threshold for week 9 in the National Center for Health Statistics (NCHS) Mortality Surveillance System is 7.4%.
NCHS data are delayed for two weeks to allow for the collection of enough data to produce stable P&I percentages.
Region and state-specific data are available at

Pediatric Deaths:
Five influenza-associated pediatric deaths were reported to CDC during week 11.
One death was associated with an influenza A virus for which subtyping was not performed and occurred during week 8 (the week ending February 24, 2018). One death was associated with an influenza A(H3) virus and occurred during week 10 (the week ending March 10, 2018). Two deaths were associated with an influenza B virus and occurred during weeks 10 and 11 (the weeks ending March 10, 2018, March 17, 2018, respectively). One death was associated with an influenza virus co-infection and occurred during week 9 (the week ending March 3, 2018).
A total of 133 influenza-associated pediatric deaths for the 2017-2018 flu season have been reported to CDC.
Additional information on pediatric deaths is available on FluView Interactive at:

Laboratory Data:
Nationally, the percentage of respiratory specimens testing positive for influenza viruses in clinical laboratories during the week ending March 17 was 15.3%.
Regionally, the three-week average percent of specimens testing positive for influenza in clinical laboratories ranged from 11.9% to 21.6%.
During the week ending March 17, of the 4,326 (15.3%) influenza-positive tests reported to CDC by clinical laboratories, 1,828 (42.3%) were influenza A viruses and 2,498 (57.7%) were influenza B viruses.
Influenza A(H3) viruses have predominanted this season. However, the proportion of influenza B viruses is increasing and during week 11, influenza B viruses were more frequently reported than influenza A viruses.
During the week ending March 17, 184 (42.5%) of the 433 influenza-positive tests reported to CDC by public health laboratories were influenza A viruses and 249 (57.5%) were influenza B viruses. Of the 167 influenza A viruses that were subtyped, 100 (59.8%) were H3N2 viruses and 67 (40.1%) were (H1N1)pdm09 viruses.
The majority of the influenza viruses collected from the United States during October 1, 2017 through March 17, 2018 were characterized antigenically and genetically as being similar to the cell-grown reference viruses representing the 2017–18 Northern Hemisphere influenza vaccine viruses.
Since October 1, 2017, CDC has tested 702 influenza A(H1N1)pdm09, 1,495 influenza A(H3N2), and 659 influenza B viruses for resistance to antiviral medications (i.e., oseltamivir, zanamivir, or peramivir). While the majority of the tested viruses showed susceptibility to the antiviral drugs, nine (1.3%) H1N1pdm09 viruses were resistant to both oseltamivir and peramivir, but were sensitive to zanamivir.

Source: CDC